science
Eli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
May 22, 4:44 AM·1m read1 source
finance.yahoo.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly announced clinical trial results for its experimental obesity drug retatrutide on May 22, 2026. The drug produced an average weight loss of 70 pounds among study participants over 80 weeks, according to the company. Eli Lilly stated that retatrutide outperformed its current obesity treatments Zepbound and Wegovy in the trial.
The company presented the findings during a public announcement.
No further details on side effects or regulatory timelines were included in the initial report. The results position retatrutide as a potential next-generation option in the obesity treatment market.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
